ARCHIVES

IOM To Advise Army On Spending $210 Mil. Breast Cancer Money

This article is from The Cancer Letter archive.

Vol. 19 No. 02 | January 8, 1993

Download PDF Visit The Full Archive

Related Articles

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

NCCN Launches Outcomes Improvement Program

August 12, 2011

Guest Editorial: Chernobyl Doctor’s Notes From Fukushima

April 1, 2011

Bush Nominates Health Policy Advisor McClellan For FDA Commissioner

September 27, 2002

NIH oncology peer reviewers are protesting the outcome of a recent meeting in which their own grant applications fared so poorly that the reviewers said they were penalized for their service.

May 6, 2005